Tactile Systems Technology, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tactile Systems Technology, Inc. (TCMD), doing business as Tactile Medical, is a medical technology company that develops, manufactures and markets at-home medical devices for the treatment of underserved chronic conditions, including lymphedema, lipedema, chronic venous insufficiency, chronic pulmonary disease and related vascular, oncology and respiratory disorders; its core products include the Flexitouch Plus system, a fully automated programmable advanced pneumatic compression device for lymphedema and chronic venous insufficiency; the Entre Plus system, another at-home pneumatic compression therapy; the Nimbl platform, a small light compact connected pneumatic compression controller with FDA clearance for upper extremity use in 2024 and commercial launch for lower extremity expansion in October 2024; the AffloVest system, a mobile high-frequency chest wall oscillation device for airway clearance therapy in chronic respiratory conditions; and the Kylee mobile application for patient education on lymphedema management. Founded in 1995 and headquartered in Minneapolis, Minnesota, the company primarily serves patients in the United States through a direct national sales force of product specialists, trainers, reimbursement experts and clinical staff, with operations focused on the home-based therapy market. In recent developments, Tactile Systems Technology raised its full-year 2025 revenue guidance to $317 million to $321 million, implying 8-10% growth, and announced a $25 million share repurchase program following strong third-quarter 2025 results that included 17% year-over-year revenue growth to $85.8 million and positive long-term clinical data for Flexitouch Plus in head and neck cancer-related lymphedema; the company also repaid a $24 million term loan, increased its revolving credit facility capacity and expanded its sales force by 15% year-over-year to 329 representatives.
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?
Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
Tactile Systems Technology (NASDAQ:TCMD) Stock Passes Below 50 Day Moving Average – Should You Sell?
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of “Moderate Buy” from Analysts
Wall Street Analysts See a 41.11% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?
Tactile Systems Technology (TCMD) is an Incredible Growth Stock: 3 Reasons Why
Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson
Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 28.34%: Read This Before Placing a Bet
Are Investors Undervaluing Tactile Systems Technology (TCMD) Right Now?
3 Reasons Why Growth Investors Shouldn't Overlook Tactile Systems Technology (TCMD)
Tactile Systems Technology (TCMD) Recently Broke Out Above the 20-Day Moving Average
Tactile Systems Technology (TCMD) Just Overtook the 50-Day Moving Average